经静脉膈肌神经刺激在机械通气脱机中的卫生经济学价值
该研究为基于RESCUE-3随机试验及真实世界索赔数据的成本-后果分析,在美国背景下比较经静脉膈肌神经刺激(tDNS)与标准治疗(SoC)在机械通气患者中的短期经济结局,并进行终身投影模型探索性分析。基础案例假设下,tDNS使机械通气利用减少2.8天、脱机成功率提高10.5%,在未计入tDNS费用前,急性期预计节省12,102美元、长期护理医院节省11,999美元。敏感性分析中成本节省结论稳健。急性期脱机改善可能使患者剩余 lifetime 获得0.10-0.68 QALYs。结论认为tDNS可能具有成本效益和高价值,但需未来终身成本-效果分析验证。
要点
- 基于RESCUE-3试验数据,tDNS组较SoC组机械通气利用减少2.8天,脱机成功率提高10.5%。
- 在未计入tDNS治疗费用前,急性期预计节省12,102美元,长期护理医院预计节省11,999美元。
- 敏感性分析采用多种临床和成本假设,成本节省结论均成立。
- 急性期脱机改善可能带来剩余 lifetime 0.10-0.68 QALYs增益,但取决于治疗费用。
- 该分析为探索性成本-后果分析,需未来终身成本-效果分析进一步验证。
适用人群与场景
- 接受机械通气的患者,具体纳入和排除标准原文未提及。
- 场景为美国急性医院和长期护理医院设置。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型为成本-后果分析,基于RESCUE-3随机试验临床数据和真实世界索赔数据,样本量、中心数原文未提及。
- 基础案例假设下,tDNS较SoC减少机械通气利用2.8天,脱机成功率提高10.5%。
- 在未计入tDNS费用前,急性期预计节省12,102美元,长期护理医院预计节省11,999美元。
- 敏感性分析采用多种临床和成本假设,成本节省结论均成立。
- 急性期脱机改善可能带来剩余 lifetime 0.10-0.68 QALYs增益。
证据类型、等级与局限
- 证据类型为基于随机试验(RESCUE-3)和真实世界数据的探索性成本-后果分析,证据等级原文未提及。
- 局限:探索性分析,需未来终身成本-效果分析验证;其他局限原文未提及。
对床旁实践的改变
- 基于探索性分析,tDNS可能通过提高脱机成功率、缩短机械通气时间,在急性期和长期护理机构中节省成本,但需考虑治疗费用,且需未来成本-效果分析确认。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Prolonged mechanical ventilation presents a substantial clinical and economic burden. Transvenous diaphragm neurostimulation (tDNS) has demonstrated an increased rate of successful weaning and reduced duration of ventilation among mechanically ventilated patients. This exploratory analysis sought to quantify the potential short-term health-economic implications in the acute hospital setting, as well as potential lifetime benefits resulting from improved weaning in mechanically ventilated patients receiving tDNS compared with the standard of care (SoC).
DESIGN, SETTING, PATIENTS: A cost-consequence analysis was conducted, reporting short-term economic outcomes for tDNS- vs. SoC-treatment strategies in a U.S. setting, based on recent clinical data from the RESCUE-3 randomized trial and real-world claims data. A lifetime projection model informed long-term survival and quality-of-life implications in an exploratory analysis. The primary outcomes included stakeholder-specific incremental costs and quality-adjusted life-year (QALY) gain with tDNS. Extensive sensitivity analyses and validations were performed.
INTERVENTIONS: None.
MEASUREMENT AND MAIN RESULTS: Under the base case assumptions, a 2.8-day reduction in mechanical ventilation utilization and 10.5% greater weaning success led to projected cost savings of $12,102 in the acute setting and $11,999 in the long-term care hospital setting, before consideration of tDNS cost. Favorable cost savings materialized across sensitivity analyses employing a range of clinical and cost assumptions. An increase in acute weaning with tDNS may lead to 0.10-0.68 QALYs gained over patients' remaining lifetime.
CONCLUSIONS: Based on these exploratory findings, improved weaning rates with tDNS will likely lead to meaningful cost savings in acute and long-term care settings, and concurrent long-term QALY gains that, depending on therapy cost, may render tDNS a cost-effective, high-value intervention. Future lifetime cost-effectiveness analyses are warranted.
参考来源
- Pietzsch JB, Ryschon AM, Mehta N, et al. Health-Economic Value of Transvenous Diaphragm Neurostimulation in Ventilator Weaning. Crit Care Med. 2026. PMID: 42479503. doi:10.1097/CCM.0000000000007262
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。